Glomerular Diseases in Children

Advances in Chronic Kidney Disease

Volumn 24, Issue 6, 2017, Pages 364-371

  Wenderfer, Scott E ^a,b   Gaut, Joseph P ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glomerulonephritis; Hematuria; Nephrotic syndrome; Pediatric; Proteinuria

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ALLELE; ANAPHYLACTOID PURPURA; CHILD; CHILD GROWTH; CHRONICITY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MANAGEMENT; DISEASE MARKER; GENETIC RISK; GLOMERULONEPHRITIS; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; KIDNEY BIOPSY; KIDNEY INJURY; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHRITIS; NEPHROTIC SYNDROME; ONSET AGE; PATIENT MONITORING; POSTINFECTIOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; RELAPSE; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES; ADOLESCENT; GLOMERULUS; PREVALENCE;

ADOLESCENT; AGE OF ONSET; CHILD; DISEASE MANAGEMENT; GLOMERULONEPHRITIS; HUMANS; KIDNEY GLOMERULUS; NEPHROTIC SYNDROME; PREVALENCE;

EID: 85037613085     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2017.09.005     Document Type: Review

References (58)

1. Sethi, S., Haas, M., Markowitz, G.S., et al. Mayo Clinic/renal pathology Society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol 27:5 (2016), 1278–1287.
2. Nester, C.M., J Falk, R., Introduction: glomerular disease update for the clinician. Clin J Am Soc Nephrol 11:9 (2016), 1662–1663.
3. Sethi, S., Etiology-based diagnostic approach to proliferative glomerulonephritis. Am J Kidney Dis 63:4 (2014), 561–566.
4. Wiggins, R.C., Alpers, C.E., Holzman, L.B., et al. Glomerular disease: Looking beyond pathology. Clin J Am Soc Nephrol 9:6 (2014), 1138–1140.
5. Mariani, L.H., Pendergraft, W.F. 3rd, Kretzler, M., Defining glomerular disease in Mechanistic terms: Implementing an Integrative biology approach in Nephrology. Clin J Am Soc Nephrol 11:11 (2016), 2054–2060.
6. Kitching, A.R., Hutton, H.L., The Players: cells involved in glomerular disease. Clin J Am Soc Nephrol 11:9 (2016), 1664–1674.
7. Rodriguez-Iturbe, B., Batsford, S., Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int 71:11 (2007), 1094–1104.
8. Wenderfer, S.E., Ruth, N.M., Brunner, H.I., Advances in the Care of children with lupus nephritis. Pediatr Res 81:3 (2017), 406–414.
9. Plumb, L.A., Oni, L., Marks, S.D., et al. Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. Pediatr Nephrol, 2017 [Epub ahead of print].
10. Muller-Deile, J., Schiffer, M., Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?. Pediatr Nephrol 31:3 (2016), 393–405.
11. Vivarelli, M., Massella, L., Ruggiero, B., et al. Minimal change disease. Clin J Am Soc Nephrol 12 (2016), 332–345.
12. Rosenberg, A.Z., Kopp, J.B., Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 12:3 (2017), 502–517.
13. Francis, J.M., Beck, L.H. Jr., Salant, D.J., Membranous nephropathy: a Journey from Bench to Bedside. Am J Kidney Dis 68:1 (2016), 138–147.
14. Nester, C.M., Barbour, T., de Cordoba, S.R., et al. Atypical aHUS: State of the art. Mol Immunol 67:1 (2015), 31–42.
15. Weening, J.J., D'Agati, V.D., Schwartz, M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:2 (2004), 241–250.
16. Trimarchi, H., Barratt, J., Cattran, D.C., et al. Oxford classification of IgA nephropathy 2016-the role of crescentic lesions: an update from the IgA nephropathy classification Working group. Kidney Int 91:5 (2017), 1014–1021.
17. Ehrenreich, T., Churg, J., Membranous nephropathy. Sommers, S., (eds.) Pathology Annual, 1968, Appleton-Century-Crofts, New York.
18. Hoxha, E., Beck, L.H. Jr., Wiech, T., et al. An Indirect immunofluorescence Method Facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol 28:2 (2017), 520–531.
19. Larsen, C.P., Messias, N.C., Silva, F.G., et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 26:5 (2013), 709–715.
20. Kanda, S., Horita, S., Yanagihara, T., et al. M-type phospholipase A2 receptor (PLA2R) glomerular staining in pediatric idiopathic membranous nephropathy. Pediatr Nephrol 32:4 (2017), 713–717.
21. Debiec, H., Guigonis, V., Mougenot, B., et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346:26 (2002), 2053–2060.
22. Debiec, H., Lefeu, F., Kemper, M.J., et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 364:22 (2011), 2101–2110.
23. Haas, M., Alport syndrome and thin glomerular basement membrane nephropathy: a practical approach to diagnosis. Arch Pathol Lab Med 133:2 (2009), 224–232.
24. Savige, J., Gregory, M., Gross, O., et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 24:3 (2013), 364–375.
25. Coppo, R., Biomarkers and targeted new therapies for IgA nephropathy. Pediatr Nephrol 32:5 (2017), 725–731.
26. Southwest Pediatric Nephrology Study Group t. Childhood nephrotic syndrome associated with diffuse mesangial hypercellularity. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 24:1 (1983), 87–94.
27. D'Agati, V.D., Kaskel, F.J., Falk, R.J., Focal segmental glomerulosclerosis. N Engl J Med 365:25 (2011), 2398–2411.
28. Ardissino, G., Dacco, V., Testa, S., et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 111:4 Pt 1 (2003), e382–e387.
29. Lovric, S., Fang, H., Vega-Warner, V., et al. Rapid detection of Monogenic causes of childhood-onset steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 9:6 (2014), 1109–1116.
30. Hinkes, B.G., Mucha, B., Vlangos, C.N., et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 119:4 (2007), e907–e919.
31. Vivante, A., Hildebrandt, F., Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol 12:3 (2016), 133–146.
32. Bierzynska, A., McCarthy, H.J., Soderquest, K., et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int 91:4 (2017), 937–947.
33. Sadowski, C.E., Lovric, S., Ashraf, S., et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 26:6 (2015), 1279–1289.
34. Ebarasi, L., Ashraf, S., Bierzynska, A., et al. Defects of CRB2 cause steroid-resistant nephrotic syndrome. Am J Hum Genet 96:1 (2015), 153–161.
35. Miyake, N., Tsukaguchi, H., Koshimizu, E., et al. Biallelic mutations in nuclear pore complex Subunit NUP107 cause early-childhood-onset steroid-resistant nephrotic syndrome. Am J Hum Genet 97:4 (2015), 555–566.
36. Braun, D.A., Sadowski, C.E., Kohl, S., et al. Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome. Nat Genet 48:4 (2016), 457–465.
37. Gee, H.Y., Zhang, F., Ashraf, S., et al. KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. J Clin Invest 125:6 (2015), 2375–2384.
38. McCarthy, H.J., Bierzynska, A., Wherlock, M., et al. Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 8:4 (2013), 637–648.
39. Sethi, S., Fervenza, F.C., Membranoproliferative glomerulonephritis–a new look at an old entity. N Engl J Med 366:12 (2012), 1119–1131.
40. Pickering, M.C., D'Agati, V.D., Nester, C.M., et al. C3 glomerulopathy: consensus report. Kidney Int 84:6 (2013), 1079–1089.
41. Bu, F., Borsa, N.G., Jones, M.B., et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol 27:4 (2016), 1245–1253.
42. Noris, M., Caprioli, J., Bresin, E., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:10 (2010), 1844–1859.
43. Fremeaux-Bacchi, V., Fakhouri, F., Garnier, A., et al. Genetics and outcome of atypical hemolytic uremic syndrome: a Nationwide French series Comparing children and adults. Clin J Am Soc Nephrol 8:4 (2013), 554–562.
44. Gaut, J.P., Jain, S., Pfeifer, J.D., et al. Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies. Mod Pathol, 2017 [Epub ahead of print].
45. Sinha, A., Gulati, A., Saini, S., et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85:5 (2014), 1151–1160.
46. Riedl, M., Thorner, P., Licht, C., C3 glomerulopathy. Pediatr Nephrol 32:1 (2017), 43–57.
47. Wenderfer, S.E., Viral-associated glomerulopathies in children. Pediatr Nephrol 30:11 (2015), 1929–1938.
48. Coppo, R., Peruzzi, L., Amore, A., et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:6 (2007), 1880–1888.
49. de Zeeuw, D., Parekh, R., Soman, S., CKD treatment: time to alter the focus to albuminuria?. Adv Chronic Kidney Dis 18:4 (2011), 222–223.
50. Mina, R., Abulaban, K., Klein-Gitelman, M., et al. Validation of the lupus nephritis clinical indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res 68:2 (2015), 195–202.
51. Dolezalova, P., Price-Kuehne, F.E., Ozen, S., et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis 72:10 (2013), 1628–1633.
52. Brunner, H.I., Bennett, M., Abulaban, K., et al. Development of a novel renal activity index of lupus nephritis in children & young adults. Arthritis Care Res 68:7 (2016), 1003–1011.
53. Abulaban, K.M., Song, H., Zhang, X., et al. Predicting decline of kidney function in lupus nephritis using urine biomarkers. Lupus 25:9 (2016), 1012–1018.
54. van Vollenhoven, R.F., Mosca, M., Bertsias, G., et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:6 (2014), 958–967.
55. Selewski, D.T., Thompson, A., Kovacs, S., et al. Patient-reported outcomes in glomerular disease. Clin J Am Soc Nephrol 12:1 (2017), 140–148.
56. Morishita, K.A., Moorthy, L.N., Lubieniecka, J.M., et al. Early outcomes in children with Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Arthritis Rheumatol 69:7 (2017), 1470–1479.
57. Moxey-Mims, M.M., Flessner, M.F., Holzman, L., et al. Glomerular diseases: Registries and clinical trials. Clin J Am Soc Nephrol 11:12 (2016), 2234–2243.
58. Gipson, D.S., Troost, J.P., Lafayette, R.A., et al. Complete remission in the nephrotic syndrome study network. Clin J Am Soc Nephrol 11:1 (2016), 81–89.